Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule. Local targets link to admitted publications; unresolved targets remain external evidence.
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
10.3171/jns.1978.49.3.0333 · 1978 · External reference
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
10.1056/nejmoa043330 · 2005 · External reference
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study
10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2 · 1983 · External reference
Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage
10.1007/s004320000171 · 2001 · External reference
Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance
2010 · External reference
The role of p53 in chemosensitivity and radiosensitivity
10.1038/sj.onc.1206949 · 2003 · External reference
The protein kinase B/Akt signalling pathway in human malignancy
10.1016/s0898-6568(01)00271-6 · 2002 · External reference
Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis
2000 · External reference
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways
2003 · External reference
The phosphatidylinositol 3-kinase AKT pathway in human cancer
10.1038/nrc839 · 2002 · External reference
The TOR pathway: a target for cancer therapy
10.1038/nrc1362 · 2004 · External reference
Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells
2010 · External reference
The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation
10.1186/1748-717x-5-108 · 2010 · External reference
Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation
2010 · External reference
Inhibition of phosphatidylinositol-3-OH kinase/Akt signaling impairs DNA repair in glioblastoma cells following ionizing radiation
10.1074/jbc.m703042200 · 2007 · External reference
Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells
10.1186/1748-717x-4-43 · 2009 · External reference
The mTOR inhibitor rapamycin suppresses DNA double-strand break repair
10.1667/rr2323.1 · 2011 · External reference
Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism
10.1016/j.ijrobp.2005.08.014 · 2005 · External reference
Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis
10.1083/jcb.200408161 · 2004 · External reference
Targeting the PI3K/Akt/mTOR pathway—beyond rapalogs
10.18632/oncotarget.188 · 2010 · External reference
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
10.1038/sj.onc.1209990 · 2006 · External reference
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment
10.1677/erc.0.0080237 · 2001 · External reference
Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002
10.1016/s0360-3016(03)00214-1 · 2003 · External reference
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
10.1158/1535-7163.mct-08-0017 · 2008 · External reference
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils
10.1371/journal.pone.0029925 · 2012 · External reference
The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma
10.1158/1078-0432.ccr-09-3022 · 2010 · External reference
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy
10.1111/j.1349-7006.2008.00891.x · 2008 · External reference
The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo
10.1371/journal.pone.0020899 · 2011 · External reference
Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations
10.1158/0008-5472.can-09-0823 · 2009 · External reference
Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature
10.1158/0008-5472.can-11-2263 · 2012 · External reference
NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity
10.1186/1748-717x-7-48 · 2012 · External reference
The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses
10.1593/neo.111512 · 2012 · External reference
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells
10.1158/1541-7786.mcr-11-0312 · 2011 · External reference
Normal expression of DNA repair proteins, hMre11, Rad50 and Rad51 but protracted formation of Rad50 containing foci in X-irradiated skin fibroblasts from radio-sensitive cancer patients
10.1038/sj.bjc.6601878 · 2004 · External reference
An optimized method for measurement of gamma-H2AX in blood mononuclear and cultured cells
10.1038/nprot.2008.93 · 2008 · External reference
Effect of electric field pulses on the viability and on the membranebound immunoglobulins of LPS-activated murine B-lymphocytes: correlation with the cell cycle
10.1002/cyto.990150107 · 1994 · External reference
NVP-BEZ235 as a new therapeutic option for sarcomas
10.1158/1078-0432.ccr-09-0816 · 2010 · External reference
mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E
10.1128/mcb.24.1.200-216.2004 · 2004 · External reference
Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s)
10.1177/1947601910392989 · 2010 · External reference
DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139
10.1074/jbc.273.10.5858 · 1998 · External reference
Integration of EGFR inhibitors with radiochemotherapy
10.1038/nrc1953 · 2006 · External reference
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma
10.1158/0008-5472.can-05-2665 · 2006 · External reference
Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility
2009 · External reference
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling
10.1128/mcb.00601-09 · 2010 · External reference
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
10.1158/2159-8290.cd-11-0085 · 2011 · External reference
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia
10.1158/0008-5472.can-10-1814 · 2010 · External reference
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
10.1158/1535-7163.mct-09-0160 · 2009 · External reference
Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors
10.1158/1541-7786.mcr-08-0366 · 2009 · External reference
